PerioTrap is developing a new class of active ingredients for gum health. Our research focuses on selectively blocking the disease-causing mechanisms of P. gingivalis – rather than on non-specific antibacterial elimination.
Traditional strategies such as antiseptics or antibiotics have a broad effect and attack the entire microbiome. PerioTrap® technology takes a different approach:
It identifies P. gingivalis as a "keystone" pathogen and specifically blocks its virulence mechanisms by inhibiting a central enzyme (QC-II). This renders the bacterium ineffective without harming beneficial bacteria.
"The decisive advance lies in the selective blocking of pathogenic mechanisms – not in the non-specific destruction of the microbiome."
CSO PerioTrap Pharmaceuticals GmbH
Blocking QC-II prevents P. gingivalis from correctly activating its gingipain enzymes. These enzymes are essential for tissue damage, invasion, and inflammatory responses.
Through this selective inhibition:
– the pathogenic biofilm is weakened
– inflammatory markers are significantly reduced
– the microbiome remains stable
This mechanism forms the basis for products that can be used daily or professionally.
"We neutralize the key pathogen without disturbing the ecological balance. This is what makes this mechanism of action so unique."
Lead Scientist PerioTrap Pharmaceuticals GmbH
PerioTrap Pharmaceuticals GmbH
Weinbergweg 22, 06120 Haale (Saale)